Kidney Cancer Survival Rate Data

By: Neal Kennedy   To calculate the kidney cancer survival rate, you must take several different factors into consideration. Generally speaking, these factors are related to the patient who has been diagnosed with kidney cancer, and the kidney cancer stage.. In gathering their survival rate statistics, researchers take the type of cancer, stage, grade and location into consideration. Factors regarding the patient that must be considered include the individual's age, general health, and ability to undergo necessary treatment. Using data reflecting these factors in recent decades, medical researchers have been able to generate some statistics for kidney cancer survival rates. Just one type of kidney cancer is shown below, but it is far more common than any other variety. It is known as renal cell carcinoma. When the kidney cancer survival rate is calculated, it's most often expressed as a percentage. That is, it's statistically normal for a certain percent of patients who have the same type of cancer at approximately the same stage to still be alive after a defined period of time. It should be said that the kidney cancer survival rate is a generalization based on a huge number of cases that occurred over a long time. There's no way to predict what will happen in any individual case. As is the case with most other diseases, the kidney cancer survival rate is measured in five year periods. In other words, a certain percentage of patients found to have kidney cancer will sur...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

The objective of this study is to evaluate overall survival (OS), cancer-specific survival (CSS), relapse-free survival, local and distant (LRFS and DRFS, respectively) rates in patients with pT3a renal cell carcinoma (RCC) considering the perirenal and/or sinus fat infiltration (FI) as prognostic factors.Materials and methodsRetrospective cohort of patients with pT3a RCC who underwent radical or partial nephrectomy. The data were extracted from the LARCG (Latin American Renal Cancer Group) database. The demographic, clinical, pathological and surgical variables were evaluated. FI was divided into 4 groups (vein, perirenal...
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
CONCLUSIONS: Infiltration of both fats increases the risk of overall and local relapse in pT3a RCC. In the same way, it is associated with a lower cancer-specific survival and should be considered as a factor of poor prognosis. PMID: 31155375 [PubMed - as supplied by publisher]
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Authors: Tags: Actas Urol Esp Source Type: research
We report a case of ureteral stump carcinoma following a radical nephrectomy for renal cell carcinoma. A 76-year-old man was diagnosed as having ascending colon cancer and a right renal carcinoma. He was treated with partial colon resection and radical nephrectomy without lymphadenectomy. The histology was renal cell carcinoma. Three years after that surgery, he complained of intermittent macrohematuria. Abdominal computed tomography (CT) suggested a solid mass in the pelvis. We then performed a biopsy with CT guidance. An epithelial tumor was suspected by immunohistochemistry. A total excision of ureter was then performed...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
ABSTRACT Purpose To assess the relationship between De Ritis (aspartate aminotransaminase [AST]/Alanine aminotransaminase [ALT]) ratio and pathological variables and whether it is an independent prognostic factor. Materials and Methods We analyzed 298 consecutive patients who underwent radical or partial nephrectomy for non-metastatic renal cell carcinoma (RCC) between 2006 and 2015. The association between De Ritis ratio and pathological variables including tumor size, presence of renal vein invasion, vena cava invasion, renal capsule infiltration, Gerota fascia invasion, renal sinus involvement, renal pelvic invasion, an...
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
This article is protected by copyright. All rights reserved.
Source: Cancer Science - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
International five-year survival rates for metastatic kidney and renal pelvis cancer are estimated at between 12-20%, indicating significant unmet clinical need for effective therapies. Currently, everolimus is a subsidised treatment option in Australia for patients who have progressive disease following first-line treatment with a tyrosine kinase inhibitor. Nivolumab is the first immunotherapy agent explored in RCC (CheckMate-025) and this study sought to assess the cost utility of nivolumab versus everolimus.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research
Authors: Lu Q, Zhuang J, Guo H Abstract The simultaneous occurrence of renal cell carcinoma (RCC) and urothelial carcinoma (UC) in the same kidney is extraordinarily rare, and is also known as multiple primary malignant tumors. The present study reports the case of a 76-year-old female with synchronous ipsilateral RCC and UC of the renal pelvis, who underwent operation, chemotherapy and reoperation when recurrence of RCC or UC was identified. Cluster of differentiation 44 (CD44) is one of the promising markers for identifying cancer stem cells in various solid tumors, along with aldehyde dehydrogenase 1 A1 (ALDH1A1...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
ABSTRACT Cancer related to hereditary syndromes corresponds to approximately 5-10% of all tumors. Among those from the genitourinary system, many tumors had been identified to be related to genetic syndromes in the last years with the advent of new molecular genetic tests. New entities were described or better characterized, especially in kidney cancer such as hereditary leiomyomatosis renal cell carcinoma (HLRCC), succinate dehydrogenase kidney cancer (SDH-RCC), and more recently BAP1 germline mutation related RCC. Among tumors from the bladder or renal pelvis, some studies had reinforced the role of germline mutations in...
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
Conditions:   Malignant Neoplasms of Urinary Tract;   Other Disorders of Kidney and Ureter;   Renal Cell Carcinoma Interventions:   Drug: MGCD516;   Drug: Nivolumab Sponsors:   M.D. Anderson Cancer Center;   Mirati Therapeutics Inc. Not yet recruiting - verified January 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Health | Kidney Cancer | Learning | Renal Cell Carcinoma | Smokers | Statistics | Study | Universities & Medical Training | Ureter and Renal Pelvis Cancer | Urology & Nephrology | Women